{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:36:14Z","timestamp":1775151374952,"version":"3.50.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/qai.0b013e3181a24906","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:07:16Z","timestamp":1245661636000},"page":"323-331","source":"Crossref","is-referenced-by-count":19,"title":["HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique"],"prefix":"10.1097","volume":"51","author":[{"given":"In\u00eas","family":"B\u00e1rtolo","sequence":"first","affiliation":[]},{"given":"Jos\u00e9","family":"Casanovas","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"Cheila","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Ana B","family":"Abecasis","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Folgosa","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Mondlane","sequence":"additional","affiliation":[]},{"given":"Rolanda","family":"Manuel","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-13-20210131","first-page":"39","article-title":"Human immunodeficiency virus type 1 infection in a community of southern Mozambique.","volume":"43","author":"Mencarini","year":"1991","journal-title":"Trop Geogr Med"},{"key":"R2-13-20210131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3109\/00365549309008563","article-title":"HIV-1 and HIV-2 antibodies in pregnant women in the City of Maputo, Mozambique. A comparative study between 1982\/1983 and 1990.","volume":"25","author":"Barreto","year":"1993","journal-title":"Scand J Infect Dis"},{"key":"R4-13-20210131","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"key":"R5-13-20210131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R6-13-20210131","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(05)67022-5","article-title":"Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.","volume":"366","author":"Sterne","year":"2005","journal-title":"Lancet"},{"key":"R7-13-20210131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.qai.0000159668.80207.5b","article-title":"Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.","volume":"40","author":"Wester","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 3","key":"R8-13-20210131","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00002030-200317003-00006","article-title":"Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda.","volume":"17","author":"Weidle","year":"2003","journal-title":"AIDS"},{"issue":"Suppl 3","key":"R9-13-20210131","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00002030-200317003-00001","article-title":"The evaluation of the HIV\/AIDS drug access initiatives in Cote dIvoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa.","volume":"17","author":"Katzenstein","year":"2003","journal-title":"AIDS"},{"key":"R10-13-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R11-13-20210131","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/01.aids.0000233572.59522.45","article-title":"Virological response to a triple nucleoside\/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.","volume":"20","year":"2006","journal-title":"AIDS"},{"key":"R12-13-20210131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/archinternmed.2007.10","article-title":"Effectiveness of antiretroviral treatment in a South African program: a cohort study.","volume":"168","author":"Fairall","year":"2008","journal-title":"Arch Intern Med"},{"key":"R13-13-20210131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(08)60693-5","article-title":"Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi.","volume":"371","author":"Jahn","year":"2008","journal-title":"Lancet"},{"key":"R14-13-20210131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","article-title":"The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.","volume":"368","author":"Gilks","year":"2006","journal-title":"Lancet"},{"key":"R15-13-20210131","first-page":"4","article-title":"HIV antiretroviral drug resistance in Africa.","volume":"6","author":"Nkengasong","year":"2004","journal-title":"AIDS Rev"},{"key":"R16-13-20210131","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2007.01.003","article-title":"HIV resistance and the developing world.","volume":"29","author":"Gupta","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"R17-13-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801302S03","article-title":"World Health Organizations global strategy for prevention and assessment of HIV drug resistance.","volume":"13","author":"Bennett","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R18-13-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350801302S07","article-title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.","volume":"13","author":"Jordan","year":"2008","journal-title":"Antivir Ther"},{"key":"R19-13-20210131","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1371\/journal.pone.0000152","article-title":"The emergence of HIV transmitted resistance in Botswana: when will the WHO detection threshold be exceeded?","volume":"2","author":"Vardavas","year":"2007","journal-title":"PLoS ONE"},{"key":"R20-13-20210131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/QCO.0b013e328013caff","article-title":"Epidemiology of antiretroviral drug resistance in drug-naive persons.","volume":"20","author":"Geretti","year":"2007","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 2","key":"R21-13-20210131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135965350801302S09","article-title":"Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.","volume":"13","author":"Pillay","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R22-13-20210131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/135965350801302S12","article-title":"Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.","volume":"13","author":"Maphalala","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R23-13-20210131","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/135965350801302S08","article-title":"Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.","volume":"13","author":"Somi","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R24-13-20210131","first-page":"83","article-title":"Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.","volume":"13","author":"Kamoto","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R25-13-20210131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","article-title":"Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.","volume":"13","author":"Abegaz","year":"2008","journal-title":"Antivir Ther"},{"key":"R27-13-20210131","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/aid.2007.0134","article-title":"Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique.","volume":"24","author":"Lahuerta","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R28-13-20210131","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jmv.20382","article-title":"Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.","volume":"76","author":"Bellocchi","year":"2005","journal-title":"J Med Virol"},{"key":"R29-13-20210131","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.micinf.2006.05.005","article-title":"Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique.","volume":"8","author":"Parreira","year":"2006","journal-title":"Microbes Infect"},{"key":"R30-13-20210131","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/aid.2005.21.306","article-title":"High genetic diversity of human immunodeficiency virus type 1 in Angola.","volume":"21","author":"Bartolo","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R33-13-20210131","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","article-title":"The CLUSTAL_XX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.","volume":"25","author":"Thompson","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"R34-13-20210131","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01734359","article-title":"Evolutionary trees from DNA sequences: a maximum likelihood approach.","volume":"17","author":"Felsenstein","year":"1981","journal-title":"J Mol Evol"},{"key":"R35-13-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/bioinformatics\/14.9.817","article-title":"MODELTEST: testing the model of DNA substitution.","volume":"14","author":"Posada","year":"1998","journal-title":"Bioinformatics"},{"key":"R37-13-20210131","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1558-5646.1985.tb00420.x","article-title":"Confidence limits on phylogenies: an approach using the bootstrap.","volume":"39","author":"Felsenstein","year":"1985","journal-title":"Evolution"},{"key":"R38-13-20210131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/sysbio\/42.2.182","article-title":"An empirical test for bootscanning as a method for assessing viral sequence relatedness.","volume":"42","author":"Hillis","year":"1993","journal-title":"Syst Biol"},{"key":"R39-13-20210131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/JVI.73.1.152-160.1999","article-title":"Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination.","volume":"73","author":"Lole","year":"1999","journal-title":"J Virol"},{"key":"R42-13-20210131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","article-title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.","volume":"21","author":"Shafer","year":"2007","journal-title":"AIDS"},{"issue":"Suppl 2","key":"R43-13-20210131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/135965350801302S13","article-title":"Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.","volume":"13","author":"Shafer","year":"2008","journal-title":"Antivir Ther"},{"key":"R45-13-20210131","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/526786","article-title":"Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.","volume":"197","author":"Pereyra","year":"2008","journal-title":"J Infect Dis"},{"key":"R46-13-20210131","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jac\/dkm276","article-title":"Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.","volume":"60","author":"Poveda","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R47-13-20210131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials.","volume":"24","author":"de Meyer","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R48-13-20210131","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1128\/JVI.00712-06","article-title":"Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.","volume":"80","author":"Baxter","year":"2006","journal-title":"J Virol"},{"key":"R50-13-20210131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-6405-4-11","article-title":"Predictors of disease progression in HIV infection: a review.","volume":"4","author":"Langford","year":"2007","journal-title":"AIDS Res Ther"},{"key":"R51-13-20210131","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/JVI.77.4.2587-2599.2003","article-title":"Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.","volume":"77","author":"Gordon","year":"2003","journal-title":"J Virol"},{"key":"R52-13-20210131","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/aid.2007.0040","article-title":"Circulating recombinant form (CRF) 37_cpx: an ocpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G.","volume":"23","author":"Powell","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R53-13-20210131","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1128\/JVI.78.22.12455-12461.2004","article-title":"Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.","volume":"78","author":"Meloni","year":"2004","journal-title":"J Virol"},{"key":"R54-13-20210131","doi-asserted-by":"crossref","first-page":"11286","DOI":"10.1128\/JVI.74.23.11286-11295.2000","article-title":"A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant.","volume":"74","author":"Piyasirisilp","year":"2000","journal-title":"J Virol"},{"key":"R55-13-20210131","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.","volume":"22","author":"Peuchant","year":"2008","journal-title":"AIDS"},{"issue":"Suppl 1","key":"R56-13-20210131","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.qai.0000248339.82567.17","article-title":"Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation.","volume":"43","author":"Pearson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R57-13-20210131","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/QAI.0b013e318153f7ba","article-title":"Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique.","volume":"46","author":"Pearson","year":"2007","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200907010-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T19:08:22Z","timestamp":1685041702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200907010-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181a24906","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}